|
ETV2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.38040000541295E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.73699999728561E-08 |
| Normal-vs-Stage2 |
1.085440E-01 |
| Normal-vs-Stage3 |
3.10560000049698E-07 |
| Normal-vs-Stage4 |
1.08550002320129E-09 |
| Stage1-vs-Stage2 |
1.855890E-02 |
| Stage1-vs-Stage3 |
4.026200E-01 |
| Stage1-vs-Stage4 |
2.262200E-02 |
| Stage2-vs-Stage3 |
1.871830E-02 |
| Stage2-vs-Stage4 |
1.460530E-03 |
| Stage3-vs-Stage4 |
2.295000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.87899995562901E-09 |
| Normal-vs-AfricanAmerican |
4.40990000000197E-05 |
| Normal-vs-Asian |
2.9422999592299E-09 |
| Caucasian-vs-AfricanAmerican |
7.468400E-01 |
| Caucasian-vs-Asian |
5.858200E-01 |
| AfricanAmerican-vs-Asian |
9.439600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.88970000003508E-06 |
| Normal-vs-Female |
1.47530000438323E-08 |
| Male-vs-Female |
7.436400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.37599999675098E-08 |
| Normal-vs-Age(41-60Yrs) |
3.70129999982538E-08 |
| Normal-vs-Age(61-80Yrs) |
8.794900E-04 |
| Normal-vs-Age(81-100Yrs) |
2.779600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.526200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.925430E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.342200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.919630E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.422200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.634200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.993820E-02 |
| Classical-VS-Follicular |
1.48330014937414E-10 |
| Classical-VS-Other |
3.474600E-01 |
| Classical-VS-Normal |
1.9391155348103E-12 |
| Tall-VS-Follicular |
2.95250490722765E-11 |
| Tall-VS-Other |
2.586100E-02 |
| Tall-VS-Normal |
1.76469949764169E-11 |
| Follicular-VS-Other |
1.228080E-02 |
| Follicular-VS-Normal |
5.914600E-01 |
| Other-VS-Normal |
3.030200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.787400E-04 |
| Normal-vs-N1 |
7.96599999963732E-07 |
| N0-vs-N1 |
2.596000E-02 |
|
|
